Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Timeline

Start Date

May 31, 2004

Conditions
HyperplasiaChronic Renal Failure
Interventions
DRUG

edifoligide (E2F Decoy)

Trial Locations (21)

10016

NYU Medical Center, New York

10025

St. Luke's Hospital, Department of Surgery, New York

10467

Montefiore Medical Center, The Bronx

14642

University of Rochester, The Center for Vascular Disease, Rochester

22908

Nephrology Clinical Research Center, Charlottesville

29605

Surgical Education, Greenville

30322

Emory University, Renal Division, Atlanta

33136

University of Miami, School of Medicine, Miami

33600

Tampa General Hospital, Tampa

33606

LifeLink Transplant Institute, Tampa

34667

Outcomes Research International, Inc., Hudson

46202

Methodist Hospital, Tower Surgical, Indianapolis

48202

Henry Ford Hospital, Detroit

48910

Thoracic & Cardiovascular Healthcare Foundation, Lansing

60612

University Transplant, Chicago

60617

Stoney Island Dialysis, Chicago

63110

St. Louis University, Division of Nephrology, St Louis

70112

Tulane Center for Abdominal Transplant, New Orleans

70808

Vascular Surgery Associates, Baton Rouge

84132

University of Utah School of Medicine, Dept of Surgery, Salt Lake City

90017

National Institute of Clinical Research, American Medical Tower, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Anesiva, Inc.

INDUSTRY

NCT00086164 - Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis | Biotech Hunter | Biotech Hunter